Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mid-Atlantic Angel Group Fund I (MAG I) is a Philadelphia-based angel investment fund focused on providing early-stage capital to high-growth companies in the Mid-Atlantic region. The fund targets sectors including life sciences, healthcare, information technology, and physical sciences. As a member-led investment vehicle, MAG I utilizes the collective expertise of its accredited investors to perform rigorous due diligence and provide strategic mentorship to its portfolio. The fund serves as a critical bridge between initial seed funding and larger institutional venture capital rounds for emerging biotech and technology firms. MAG I was established in partnership with Ben Franklin Technology Partners of Southeastern Pennsylvania to foster regional innovation and economic growth.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mid-Atlantic Angel Group Fund I.